Genincode Plc (9PL)

Overview

GENinCode Plc is at the forefront of pioneering genetic testing, focusing on the development and commercialization of clinical genetic tests aimed at providing predictive analysis of risks to patients' health based on their genetic makeup. Operating both in the United Kingdom and internationally, GENinCode leverages cutting-edge predictive technology to furnish patients and physicians with essential preventative care and treatment strategies. The company employs a blend of clinical algorithms and artificial intelligence to offer advanced patient risk assessment, thereby predicting the onset of diseases. Incorporated in 2018, GENinCode Plc has its headquarters in Manchester, United Kingdom, positioning itself as a leader in the integration of genetic science into preventative healthcare.

Products and Services

• Cardio inCode: A patented genetic test designed to assess cardiovascular risk. This test aids individuals in adopting preventative measures against cardiovascular diseases by evaluating their genetic predisposition to such conditions.
• Lipid inCode: Specializes in the diagnosis of familial hypercholesterolemia through genetic analysis. By identifying genetic markers associated with this condition, the test facilitates early intervention and management of cholesterol levels, helping to prevent related cardiovascular diseases.
• SUDD inCode: A diagnostic tool for investigating the genetic causes behind sudden cardiac death and familial heart disease. This test plays a critical role in the early detection and prevention of heart conditions that could lead to sudden death, providing valuable information for patient care planning.
• Thrombo inCode: Focuses on the diagnosis of hereditary thrombophilia and the evaluation of an individual's risk of thrombosis. By uncovering genetic predispositions to blood clotting disorders, this test is instrumental in preventing thrombotic events through tailored medical intervention.
• Thrombo inCode Reproductive Health: An extension of the Thrombo inCode test, specifically catering to reproductive health. It offers insights into the risks of thrombophilia and its implications for future pregnancies, facilitating better-informed decisions and management strategies related to reproductive health and family planning.